3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Urinary Bladder Neoplasms
14
Non-Muscle Invasive Bladder Neoplasms
10
Colorectal Neoplasms
7
Appendiceal Neoplasms
6
Anus Neoplasms
6
Peritoneal Neoplasms
5
Carcinoma, Transitional Cell
5
Stomach Neoplasms
2
Pseudomyxoma Peritonei
2
Ovarian Neoplasms
2
Uterine Neoplasms
1
Urothelial Carcinoma of the Bladder
1
Urologic Neoplasms
1
Urologic Diseases
1
Urogenital Neoplasms
1
Urogenital Diseases
1
Urinary Bladder Diseases
1
Squamous Cell Carcinoma of Head and Neck
1
Sarcoma
1
Recurrence
1
Rectal Neoplasms
1
Pleural Neoplasms
1
Peritoneal Diseases
1
Neoplasms by Site
1
Neoplasms
1
Neoplasm Metastasis
1
Necrosis
1
Nasopharyngeal Carcinoma
1
Mediastinal Neoplasms
1
Male Urogenital Diseases
1
Interventions
pembrolizumab
12
Pemetrexed
9
Cisplatin
9
Nivolumab
8
Carboplatin
8
Ipilimumab
7
Cyclophosphamide
6
fludarabine
5
durvalumab
4
tremelimumab
2
Radiotherapy, Intensity-Modulated
2
Gemcitabine
2
Cerebral Decortication
2
tocilizumab
1
tislelizumab
1
tazemetostat
1
sotorasib
1
ruxolitinib
1
osimertinib
1
olaparib
1
obinutuzumab
1
naptumomab estafenatox
1
fludarabine phosphate
1
decitabine and cedazuridine drug combination
1
bintrafusp alfa protein, human
1
avelumab
1
atezolizumab
1
Tumor Burden
1
Tablets
1
Saline Solution
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Mesothelioma
×
Mitomycin
×
1 year
×
Clear all
No trials found.